

1 **Efficacy and Safety of neoadjuvant stereotactic body radiotherapy plus adebrelimab and**  
2 **chemotherapy for triple-negative breast cancer: A pilot study**

3

4 **Authors:** Guanglei Chen<sup>1,2,3†</sup>, Xi Gu<sup>1,2,3†</sup>, Xu Zhang<sup>1†</sup>, Xiaopeng Yu<sup>1†</sup>, Yu Zhang<sup>1,4</sup>, Jinqi Xue<sup>1,2,3</sup>,  
5 Ailin Li<sup>1</sup>, Yi Zhao<sup>1</sup>, Guijin He<sup>1</sup>, Meiyue Tang<sup>1</sup>, Fei Xing<sup>1</sup>, Jianqiao Yin<sup>1</sup>, Xiaobo Bian<sup>1</sup>, Ye Han<sup>1</sup>,  
6 Shuo Cao<sup>1</sup>, Chao Liu<sup>1,2,3</sup>, Xiaofan Jiang<sup>1,2,3</sup>, Keliang Zhang<sup>5</sup>, Yan Xia<sup>6</sup>, Huajun Li<sup>6</sup>, Nan Niu<sup>1,2,3</sup>,  
7 Caigang Liu<sup>1,2,3\*</sup>

8

9 **Author Affiliations:**

10 <sup>1</sup> Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China;

11 <sup>2</sup> Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical  
12 University, Shenyang, China;

13 <sup>3</sup> Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province,  
14 Shenyang, China.;

15 <sup>4</sup> Department of Gastrointestinal Surgery, Yantai Affiliated Hospital of Binzhou Medical University,  
16 Yantai, China;

17 <sup>5</sup> Liaoning Center for Drug Evaluation and Inspection, Shenyang, China;

18 <sup>6</sup> Jiangsu Hengrui Pharmaceuticals, Shanghai, China.

19

20 **Correspondence to**

21 Caigang Liu, Department of Oncology, Shengjing Hospital of China Medical University,  
22 Shenyang 110004, China.

23 E-mail: liucg@sj-hospital.org

24

25 **Abstract**

26 **Background:** Emerging data have supported the immunostimulatory role of radiotherapy, which  
27 could exert a synergistic effect with immune checkpoint inhibitors (ICIs). With proven effective but  
28 suboptimal efficacy of ICI and chemotherapy in triple-negative breast cancer (TNBC), we designed  
29 a pilot study to explore the efficacy and safety of neoadjuvant stereotactic body radiotherapy (SBRT)  
30 plus adbrelimab and chemotherapy in TNBC patients.

31 **Methods:** Treatment-naïve TNBC patients received two cycles of intravenous adbrelimab  
32 (20mg/kg, every 3 weeks), and SBRT (24Gy/3f, every other day) started at the second cycle, then  
33 followed by six cycles of adbrelimab plus nab-paclitaxel (125 mg/m<sup>2</sup> on days 1 and 8) and  
34 carboplatin (area under the curve 6 mg/mL per min on day 1) every 3 weeks. The surgery was  
35 performed within 3-5 weeks after the end of neoadjuvant therapy. Primary endpoint was  
36 pathological complete response (pCR, ypT0/is ypN0). Secondary endpoints included objective  
37 response rate (ORR), residual cancer burden (RCB) 0-I and safety.

38 **Results:** 13 patients were enrolled and received at least one dose of therapy. 10 (76.9%) patients  
39 completed SBRT and were included in efficacy analysis. 90% (9/10) of patients achieved pCR, both  
40 RCB 0-I and ORR reached 100% with 3 patients achieved complete remission. Adverse events (AEs)  
41 of all-grade and grade 3-4 occurred in 92.3% and 53.8%, respectively. 1 (7.7%) patient had  
42 treatment-related serious AEs. No radiation-related dermatitis or death occurred.

43 **Conclusions:** Adding SBRT to adbrelimab and neoadjuvant chemotherapy led to a substantial  
44 proportion of pCR with acceptable toxicities, supporting further exploration of this combination in  
45 TNBC patients.

46 **Funding:** This research did not receive any specific grant from funding agencies in the public,

47 commercial, or not-for-profit sectors.

48 **Clinical trial number:** NCT05132790.

49

50 **Introduction**

51 Triple-negative breast cancer (TNBC), defined as estrogen receptor, progesterone receptor and  
52 human epidermal growth factor receptor 2 (HER2) negative, accounts for approximately 10-20% of  
53 all breast cancers(Costa et al., 2017). Characterized by higher tumor mutation burden and more  
54 intensive tumor-infiltrating lymphocytes (TILs) in tumor microenvironment (TME)(Loi et al., 2019),  
55 TNBC is more sensitive to immune checkpoint inhibitors (ICIs) than any other subtypes(Keenan &  
56 Tolaney, 2020). Nowadays, the combination with pembrolizumab (a PD-1 blockade) and standard  
57 chemotherapy is recommended for TNBC patients with stage II-III according to National  
58 Comprehensive Cancer Network (NCCN) guidelines(Gradishar et al., 2022). However, there is still  
59 around 40% of TNBC patients cannot achieve a pathological complete response (pCR) according  
60 to KEYNOTE-522 (Schmid et al., 2020) and IMpassion031 (Mittendorf et al., 2020) trials, which  
61 calls for more promising strategies.

62 Radiotherapy (RT) is the most critical locoregional treatment in solid malignancies and  
63 approximately half of patients may receive RT during the entire treatment period (Atun et al., 2015;  
64 Citrin, 2017). Stereotactic body radiotherapy (SBRT), a novel technique with higher doses of  
65 radiation delivery to the tumor lesion in a smaller number of fractions, can shorten treatment  
66 duration and reduce exposure to the surrounding tissues (Chen et al., 2020). SBRT has already  
67 been widely applied to advanced breast cancer as salvage treatment targeting to osseous and brain  
68 metastasis or other oligometastatic sites (Nicosia et al., 2022; Viani et al., 2021). Preoperative SBRT  
69 may be advantageous for downstaging the tumor to enable breast conservation and improving pCR  
70 rate (Piras et al., 2023), with multiple trials investigating neoadjuvant SBRT in various malignancies

71 (Holyoake et al., 2021; Kishi et al., 2020; Liu et al., 2022; Novikov et al., 2021) are currently  
72 ongoing. In addition, preclinical evidence suggested that SBRT has immunomodulatory properties  
73 by inducing cancer cells necrosis and releasing neoantigens to boost neoantigen-specific immune  
74 response and upregulate the expression of PD-L1 on tumor cells (Deng et al., 2014; Han et al., 2022;  
75 Park et al., 2015). Given these, it would be promising to combine SBRT with ICIs and chemotherapy  
76 under the neoadjuvant setting.

77 Therefore, we conducted a prospective pilot study to determine the efficacy and safety of  
78 neoadjuvant SBRT in combination with adebrelimab (SHR-1316), a potent selective PD-L1  
79 inhibitor, plus nab-paclitaxel and carboplatin in patients with newly-diagnosed early or locally  
80 advanced TNBC, to validate the feasibility of this novel regimen in neoadjuvant treatment of TNBC.

81

## 82 **Methods**

### 83 **Patients**

84 Previously untreated patients aged between 18 and 75 years, with histologically confirmed invasive  
85 triple-negative breast cancer (defined as negative estrogen receptor, progesterone receptor and  
86 HER2 status by American Society of Clinical Oncology/College of American Pathologists  
87 guidelines) and pathological tumor size  $\geq 2.0$  cm in MRI assessment, were eligible for enrollment.  
88 Other inclusion criteria included Eastern Cooperative Oncology Group performance score of 0-1,  
89 adequate marrow, hepatic, renal and cardiac function.

90 Key exclusion criteria included bilateral, inflammatory or occult breast cancer; active or a history  
91 of autoimmune disease; use of glucocorticoids or other immunosuppressive therapy within 2 weeks

92 before the first study dose; a history of interstitial pneumonia; active tuberculosis; pregnancy,  
93 lactation, and refusal to use contraception.

94

#### 95 **Study design and treatment**

96 This single-arm, prospective study was approved by the Institutional Review Board of Shengjing  
97 Hospital, China Medical University and performed in accordance with the Declaration of Helsinki  
98 and Good Clinical Practice. Written informed consent was obtained from each patient. This study  
99 was reported following the Strengthening the Reporting of Observational Studies in Epidemiology  
100 (STROBE) reporting guidelines.

101 All patients intravenously received 8 cycles of adrebrimab (20 mg/kg every 3 weeks). SBRT  
102 (24Gy/3f) targeted to breast lesion started at the second cycle every other day, and 6 cycles of nab-  
103 paclitaxel (125 mg/m<sup>2</sup> on days 1 and 8) and carboplatin (area under the curve 6 mg/mL per min on  
104 day 1) was given every 3 weeks since the third cycle.

105 Patients who completed or discontinued the neoadjuvant treatment could receive surgery. If  
106 disease progressed during the neoadjuvant phase, the patient would either proceed to surgery or  
107 receive alternative neoadjuvant therapy. Surgery was performed 3-5 weeks after the last dose of  
108 neoadjuvant therapy. Recommended surgery and adjuvant therapy were administered as per local  
109 guidelines or institutional standards.

110

#### 111 **Outcomes**

112 The primary endpoint was pCR rate in the breast and axillary lymph nodes (ypT0/is ypN0).

113 Secondary endpoints included ORR before surgery (defined as the proportion of patients with  
114 complete or partial response according to the Response Evaluation Criteria in Solid Tumors  
115 [RECIST] version 1.1), the proportion of residual cancer burden (RCB) 0-I, and safety according to  
116 the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

117

## 118 **Statistical analysis**

119 Efficacy was assessed in the modified intention-to-treat population, which included patients who  
120 had undergone radiotherapy. Safety was evaluated in all recruited patients who received at least one  
121 dose of study drug. All statistical analyses were conducted using SAS 9.4 (North Carolina, USA).  
122 Continuous data are presented as mean and standard deviation (SD), or mean and 95% confidence  
123 interval (CI). Categorical data are expressed as frequency and percentage. The 95% CIs of  
124 pathological complete response rate, proportion of patients with RCB 0-I, and ORR were estimated  
125 using the Clopper-Pearson method.

126

## 127 **Results**

### 128 **Patient characteristics**

129 Between December 2021 and January 2023, 13 patients were enrolled in the trial (*Figure 1*). The  
130 baseline characteristics are shown in *Table 1*. The median age was 51 years (range 31-68) and the  
131 median tumor size was 33mm (range, 22-72). Lymph node involvement was seen in 53.8% (7/13)  
132 patients and 46.2% (6/13) patients had stage III breast cancer at baseline.

133

134 **Outcomes**

135 Among the 13 treated patients, 2 (15.4%) were excluded after the first dose of adbrelimab due to  
136 protocol deviation and 1 (7.7%) discontinued after the second dose of adbrelimab due to adverse  
137 event, thus only 10 (76.9%) who underwent neoadjuvant SBRT and surgery (the modified intention-  
138 to-treat population) were available for efficacy evaluation (**Figure 1**). 9 of the ten efficacy-evaluable  
139 patients (90%, 95% CI 55.5%-99.8%) achieved pCR in the breast and axillary lymph nodes, and the  
140 rates of RCB 0-I was 100% (95% CI 67.9%-100.0%). The radiologic ORR was 100% (95% CI  
141 67.9%-100.0%, **Table 2 and Figure 2**) with 3 patients achieved complete radiographic response. 4  
142 patients with positive lymph node at baseline had nodal downstaging to N0 after neoadjuvant  
143 treatment.

144

145 **Safety**

146 AEs were reported in all 13 patients (**Table 3**). The incidence of any grade AEs was 92.4%. The  
147 grade 3 or higher treatment-related adverse events occurred in 53.9% of the patients, including  
148 neutropenia (30.8%), anemia (7.7%), leukopenia (7.7%), thrombocytopenia (7.7%), creatine  
149 phosphokinase elevation (7.7%) and diarrhea (7.7%). Immune-related adverse events of any grade  
150 occurred in 23.1% of the patients with 1 (7.7%) patient experienced serious adverse events due to  
151 immune-mediated myositis. 2 patients required a dose reduction of carboplatin due to AEs but  
152 ultimately complete the prescribed treatment. There were no therapy-related death and no radiation-  
153 related dermatitis and skin hyperpigmentation.

154



155 **Discussion**

156 This pioneering study reported the efficacy and safety of neoadjuvant SBRT in combination with  
157 adbreliimab, nab-paclitaxel and carboplatin in TNBC patients. This new therapeutic regimen  
158 achieved promising anti-tumor activity with pCR rate of 90%, and the RCB 0-I and ORR rate of  
159 100%, respectively. More importantly, this combinatory therapeutic strategy was well tolerated in  
160 this population.

161 For TNBC patients who are candidates for preoperative therapy, neoadjuvant chemotherapy  
162 combined with ICIs has already achieved pCR rate of 58-64.8% in KEYNOTE-522(Schmid et al.,  
163 2020) and IMpassion031 study (Mittendorf et al., 2020). In our study, the addition of SBRT to  
164 adbreliimab and standard neoadjuvant chemotherapy achieved a significantly higher percentage of  
165 pCR (90%). Since the dose of SBRT at 24Gy in 3 fractions (bioequivalent dose [BED] = 43.2Gy)  
166 was lower than conventional preoperative radiotherapy dose (45-50Gy/23-25 fractions) (Ahmed et  
167 al., 2021), we thought that SBRT (24Gy/3f) alone could rarely achieve pCR. We speculated that the  
168 SBRT (24Gy/3f) may exert synergy with immunochemotherapy, and not just local tumor  
169 eradication effects.

170 Recently, SBRT has been preclinically identified as exerting immunomodulatory effects and  
171 synergizing anticancer immune responses combined with ICIs (Deng et al., 2014; Park et al., 2015).  
172 Pilonis et al (Pilonis et al., 2020) discovered that SBRT (two doses of 12 Gy) improved the  
173 therapeutic effects of PD-1 in a triple-negative breast cancer murine model, and this effect was  
174 enhanced by the addition of chemotherapy. TONIC trial demonstrated that SBRT (24Gy/3f)  
175 combined with nivolumab can increase the proportion of patients free of progression at 24 weeks

176 than nivolumab alone (17% vs 8%) (Voorwerk et al., 2019). Another small sample research has  
177 indicated that preoperative SBRT (19.5-31.5Gy/3f) with neoadjuvant chemotherapy may result in  
178 fair pCR rates of 36%, with the maximum response (pCR 67%) was obtained at a dose of 25.5Gy/3f  
179 (Bondiau et al., 2013), as well as no increase in the incidences of early or late-term adverse events  
180 (AEs) (Piras et al., 2023; Takanen et al., 2022). Together, these studies suggested SBRT may have  
181 strong immunomodulatory effects, rendering a synergistic antitumor effect with immunotherapy  
182 and chemotherapy.

183 Another study exploring SBRT(24Gy/3f) in combination with pembrolizumab plus  
184 chemotherapy in a neoadjuvant setting for TNBC patients also achieved a promising pCR rate of  
185 74% (PEARL) (McArthur et al., 2022). Noteworthy, PEARL study chose taxane-based  
186 chemotherapy in which 52% of patients received platinum, while our study used nab-paclitaxel and  
187 carboplatin-based regimens. It is well-established that neoadjuvant chemotherapy containing  
188 platinum has shown an increase in pCR rates of approximately 15.1% in TNBC patients (Poggio et  
189 al., 2018). Additionally, the IMpassion 130 (Emens et al., 2021) and IMpassion 131 (Miles et al.,  
190 2021) studies have suggested that nab-paclitaxel combined with ICIs may exhibit greater efficacy  
191 than paclitaxel. Thus, it is hypothesized that the selection of a chemotherapy regimen may contribute  
192 to the difference of pCR rates between the PEARL and our study (74% vs 90%). Consequently, it  
193 is imperative to determine the optimal neoadjuvant chemotherapy partners for ICIs in TNBC  
194 population.

195 Adverse events observed in our study were generally consistent with the known safety profiles  
196 of neoadjuvant therapy for TNBC patients in KEYNOTE-522 (Schmid et al., 2020) and

197 IMpassion031 (Mittendorf et al., 2020) trials. The addition of SBRT did not increase any grades or  
198 grade 3 or above AEs, which were 92.3% vs 99% and 53.8% vs 57-76.8%, respectively.  
199 Furthermore, consistent with the customary toxic effects observed in lung cancers with adebrelimab  
200 plus carboplatin-based chemotherapy regimen (Wang et al., 2022; Yan et al., 2023), the addition of  
201 SBRT neither brought new AEs nor increased the incidences of grade 3 or higher or serious AEs in  
202 our population.

203 Our study had several limitations including a non-comparative preliminary trial with relatively  
204 small sample size, thereby impeding the comparison of our data with historical data due to  
205 insufficient statistical power. Thus, further prospective randomized clinical trial required to validate  
206 these outcomes is currently at the planning stage.

207 In conclusion, the addition of SBRT to adebrelimab and neoadjuvant platinum-containing therapy  
208 showed the possibility of a convenient and feasible regimen for TNBC with promising efficacy and  
209 acceptable toxicities. Neoadjuvant radiotherapy may enhance the response to immunochemotherapy  
210 through activating tumor microenvironment. Further confirmation of these findings in large-scale  
211 study is currently underway.

212

213 **Acknowledgments**

214 Jiangsu Hengrui Pharmaceuticals Co., Ltd provided the study drug adebrelimab free of charge for  
215 patients enrolled in the study. We thank the patients and their families involved in this study.

216

217 **Additional information**

218 **Conflict of interest**

219 Yan Xia and Huajun Li are the employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd. No other  
220 potential conflicts of interest were reported.

221

222 **Funding**

223 This research did not receive any specific grant from funding agencies in the public, commercial,  
224 or not-for-profit sectors.

225

226 **Authors' contributions**

227 G. Chen, Data curation, methodology. X. Gu, Data curation, Methodology. X. Zhang, Methodology.

228 X. Yu, Methodology. Y. Zhang: Data curation, formal analysis, methodology. J. Xue, Methodology.

229 A. Li, Conceptualization, methodology. Y. Zhao, Methodology. G. He, Methodology. M. Tang,

230 Data curation. F. Xing, Methodology. J. Yin, Methodology. X. Bian, Methodology. Y. Han,

231 Methodology. S. Cao, Methodology. C. Liu, Formal analysis, methodology. X. Jiang, Writing-

232 original draft. K. Zhang, Methodology. Y. Xia, Formal analysis. H. Li, Formal analysis. N. Niu,

233 Validation, data curation, formal analysis, methodology, writing–review and editing. Caigang Liu,

234 Conceptualization, supervision, project administration, writing–review and editing.

235

236 **Author ORCIDs**

237 Caigang Liu <https://orcid.org/0000-0003-2083-235X>

238

239 **Ethics approval and consent to participate**

240 The study was approved by Institutional Review Board of Shengjing Hospital, China Medical

241 University and performed, according to the Declaration of Helsinki and Good Clinical Practice

242 guidelines. Written informed consent was obtained from each patient.

243

244 **Consent for publication**

245 All authors have read and approved the final version of this manuscript.

246

247 **Data availability statement**

248 The raw clinical and imaging data are protected due to patient privacy laws. The datasets generated

249 and/or analyzed during the current study are restricted from public access by related policy and law,

250 but available from the corresponding author upon reasonable request for 10 years; de-identified

251 clinical data and experimental data are available on request sharing, which will need the approval

252 of the Institutional Ethical Committees. De-identified data will then be transferred to the inquiring

253 investigator over secure file transfer.

254

## 255 **References**

- 256 Ahmed, M., Jozsa, F., & Douek, M. (2021). A systematic review of neo-adjuvant radiotherapy in the  
257 treatment of breast cancer. *Ecancermedicalscience*, 15, 1175.  
258 <https://doi.org/10.3332/ecancer.2021.1175>  
259
- 260 Atun, R., Jaffray, D. A., Barton, M. B., Bray, F., Baumann, M., Vikram, B., Hanna, T. P., Knaul, F. M.,  
261 Lievens, Y., Lui, T. Y., Milosevic, M., O'Sullivan, B., Rodin, D. L., Rosenblatt, E., Van Dyk, J.,  
262 Yap, M. L., Zubizarreta, E., & Gospodarowicz, M. (2015, Sep). Expanding global access to  
263 radiotherapy. *Lancet Oncol*, 16(10), 1153-1186. [https://doi.org/10.1016/S1470-](https://doi.org/10.1016/S1470-2045(15)00222-3)  
264 [2045\(15\)00222-3](https://doi.org/10.1016/S1470-2045(15)00222-3)  
265
- 266 Bondiau, P. Y., Courdi, A., Bahadoran, P., Chamorey, E., Queille-Roussel, C., Lallement, M., Birtwisle-  
267 Peyrottes, I., Chapellier, C., Pacquelet-Cheli, S., & Ferrero, J. M. (2013, Apr 1). Phase 1  
268 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant  
269 chemotherapy for breast cancer. *Int J Radiat Oncol Biol Phys*, 85(5), 1193-1199.  
270 <https://doi.org/10.1016/j.ijrobp.2012.10.034>  
271
- 272 Chen, Y., Gao, M., Huang, Z., Yu, J., & Meng, X. (2020, Jul 28). SBRT combined with PD-1/PD-L1  
273 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future  
274 challenges. *J Hematol Oncol*, 13(1), 105. <https://doi.org/10.1186/s13045-020-00940-z>  
275
- 276 Citrin, D. E. (2017, Sep 14). Recent Developments in Radiotherapy. *N Engl J Med*, 377(11), 1065-  
277 1075. <https://doi.org/10.1056/NEJMra1608986>  
278
- 279 Costa, R., Shah, A. N., Santa-Maria, C. A., Cruz, M. R., Mahalingam, D., Carneiro, B. A., Chae, Y. K.,  
280 Cristofanilli, M., Gradishar, W. J., & Giles, F. J. (2017, Feb). Targeting Epidermal Growth  
281 Factor Receptor in triple negative breast cancer: New discoveries and practical insights for  
282 drug development. *Cancer Treat Rev*, 53, 111-119.  
283 <https://doi.org/10.1016/j.ctrv.2016.12.010>  
284
- 285 Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y. X. (2014, Feb).  
286 Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.  
287 *J Clin Invest*, 124(2), 687-695. <https://doi.org/10.1172/JCI67313>  
288
- 289 Emens, L. A., Adams, S., Barrios, C. H., Dieras, V., Iwata, H., Loi, S., Rugo, H. S., Schneeweiss, A.,  
290 Winer, E. P., Patel, S., Henschel, V., Swat, A., Kaul, M., Molinero, L., Patel, S., Chui, S. Y., &  
291 Schmid, P. (2021, Aug). First-line atezolizumab plus nab-paclitaxel for unresectable,  
292 locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall  
293 survival analysis. *Ann Oncol*, 32(8), 983-993.  
294 <https://doi.org/10.1016/j.annonc.2021.05.355>  
295

- 296 Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Burstein,  
297 H. J., Chew, H., Dang, C., Elias, A. D., Giordano, S. H., Goetz, M. P., Goldstein, L. J., Hurvitz,  
298 S. A., Isakoff, S. J., Jankowitz, R. C., Javid, S. H., Krishnamurthy, J., Leitch, M., Lyons, J.,  
299 Mortimer, J., Patel, S. A., Pierce, L. J., Rosenberger, L. H., Rugo, H. S., Sitapati, A., Smith, K.  
300 L., Smith, M. L., Soliman, H., Stringer-Reasor, E. M., Telli, M. L., Ward, J. H., Wisinski, K. B.,  
301 Young, J. S., Burns, J., & Kumar, R. (2022, Jun). Breast Cancer, Version 3.2022, NCCN  
302 Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*, 20(6), 691-722.  
303 <https://doi.org/10.6004/jnccn.2022.0030>  
304
- 305 Han, M. G., Wee, C. W., Kang, M. H., Kim, M. J., Jeon, S. H., & Kim, I. A. (2022, May 29). Combination  
306 of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-  
307 Negative Breast Cancer Model. *Cancers (Basel)*, 14(11).  
308 <https://doi.org/10.3390/cancers14112692>  
309
- 310 Holyoake, D. L. P., Robinson, M., Silva, M., Grose, D., McIntosh, D., Sebag-Montefiore, D.,  
311 Radhakrishna, G., Mukherjee, S., & Hawkins, M. A. (2021, Feb). SPARC, a phase-I trial of  
312 pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic  
313 cancer. *Radiother Oncol*, 155, 278-284. <https://doi.org/10.1016/j.radonc.2020.11.007>  
314
- 315 Keenan, T. E., & Tolaney, S. M. (2020, Apr). Role of Immunotherapy in Triple-Negative Breast  
316 Cancer. *J Natl Compr Canc Netw*, 18(4), 479-489.  
317 <https://doi.org/10.6004/jnccn.2020.7554>  
318
- 319 Kishi, N., Kanayama, N., Hirata, T., Ohira, S., Wada, K., Kawaguchi, Y., Konishi, K., Nagata, S.,  
320 Nakatsuka, S. I., Marubashi, S., Tomokuni, A., Wada, H., Kobayashi, S., Tomita, Y., &  
321 Teshima, T. (2020, Mar 5). Preoperative Stereotactic Body Radiotherapy to Portal Vein  
322 Tumour Thrombus in Hepatocellular Carcinoma: Clinical and Pathological Analysis. *Sci*  
323 *Rep*, 10(1), 4105. <https://doi.org/10.1038/s41598-020-60871-0>  
324
- 325 Liu, Y., Veale, C., Hablitz, D., Krontiras, H., Dalton, A., Meyers, K., Dobelbower, M., Lancaster, R.,  
326 Bredel, M., Parker, C., Keene, K., Thomas, E., & Boggs, D. (2022). Feasibility and Short-  
327 Term Toxicity of a Consecutively Delivered Five Fraction Stereotactic Body Radiation  
328 Therapy Regimen in Early-Stage Breast Cancer Patients Receiving Partial Breast Irradiation.  
329 *Front Oncol*, 12, 901312. <https://doi.org/10.3389/fonc.2022.901312>  
330
- 331 Loi, S., Drubay, D., Adams, S., Pruneri, G., Francis, P. A., Lacroix-Triki, M., Joensuu, H., Dieci, M. V.,  
332 Badve, S., Demaria, S., Gray, R., Munzone, E., Lemonnier, J., Sotiriou, C., Piccart, M. J.,  
333 Kellokumpu-Lehtinen, P. L., Vingiani, A., Gray, K., Andre, F., Denkert, C., Salgado, R., &  
334 Michiels, S. (2019, Mar 1). Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled  
335 Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. *J Clin Oncol*,  
336 37(7), 559-569. <https://doi.org/10.1200/JCO.18.01010>  
337

- 338 McArthur, H. L., Shiao, S., Karlan, S., Basho, R., Amersi, F., Burnison, M., Mirhadi, A., Chung, A.,  
339 Chung, C. T., Dang, C., Richardson, H., Giuliano, A. E., Kapoor, N., Larkin, B., Godinez, H.,  
340 Dunn, S. A., Khameneh, N. H., Knott, S., McAndrew, P., Mita, M., Park, D. J., Abaya, C., Chen,  
341 J. H., Ly, A., Bossuyt, V., & Ho, A. (2022). Abstract PD10-01: The PEARL trial: Pre-operative  
342 pembrolizumab with radiation therapy in early stage triple negative breast cancer. *Cancer*  
343 *Research*, *82*(4\_Supplement), PD10-01-PD10-01. [https://doi.org/10.1158/1538-](https://doi.org/10.1158/1538-7445.Sabcs21-pd10-01)  
344 [7445.Sabcs21-pd10-01](https://doi.org/10.1158/1538-7445.Sabcs21-pd10-01)  
345
- 346 Miles, D., Gligorov, J., Andre, F., Cameron, D., Schneeweiss, A., Barrios, C., Xu, B., Wardley, A., Kaen,  
347 D., Andrade, L., Semiglazov, V., Reinisch, M., Patel, S., Patre, M., Morales, L., Patel, S. L.,  
348 Kaul, M., Barata, T., O'Shaughnessy, J., & investigators, I. M. (2021, Aug). Primary results  
349 from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of  
350 first-line paclitaxel with or without atezolizumab for unresectable locally  
351 advanced/metastatic triple-negative breast cancer. *Ann Oncol*, *32*(8), 994-1004.  
352 <https://doi.org/10.1016/j.annonc.2021.05.801>  
353
- 354 Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata,  
355 H., Telli, M. L., Ferrario, C., Punie, K., Penault-Llorca, F., Patel, S., Duc, A. N., Liste-Hermoso,  
356 M., Maiya, V., Molinero, L., Chui, S. Y., & Harbeck, N. (2020, Oct 10). Neoadjuvant  
357 atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based  
358 chemotherapy versus placebo and chemotherapy in patients with early-stage triple-  
359 negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. *Lancet*,  
360 *396*(10257), 1090-1100. [https://doi.org/10.1016/S0140-6736\(20\)31953-X](https://doi.org/10.1016/S0140-6736(20)31953-X)  
361
- 362 Nicosia, L., Figlia, V., Ricottone, N., Cuccia, F., Mazzola, R., Giaj-Levra, N., Ricchetti, F., Rigo, M.,  
363 Jafari, F., Maria Magrini, S., Girlando, A., & Alongi, F. (2022, Aug). Stereotactic body  
364 radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer  
365 patients. *Clin Exp Metastasis*, *39*(4), 581-588. [https://doi.org/10.1007/s10585-022-](https://doi.org/10.1007/s10585-022-10167-6)  
366 [10167-6](https://doi.org/10.1007/s10585-022-10167-6)  
367
- 368 Novikov, S. N., Gafton, G. I., Ebert, M. A., Fedosova, E. A., Melnik, J. S., Zinovev, G. V., Gafton, I. G.,  
369 Sinyachkin, M. S., & Kanaev, S. V. (2021, Aug). Preoperative stereotactic ablative body  
370 radiotherapy with postoperative conventional irradiation of soft tissue sarcomas: Protocol  
371 overview with a preliminary safety report. *Radiother Oncol*, *161*, 126-131.  
372 <https://doi.org/10.1016/j.radonc.2021.05.025>  
373
- 374 Park, S. S., Dong, H., Liu, X., Harrington, S. M., Krco, C. J., Grams, M. P., Mansfield, A. S., Furutani, K.  
375 M., Olivier, K. R., & Kwon, E. D. (2015, Jun). PD-1 Restrains Radiotherapy-Induced  
376 Abscopal Effect. *Cancer Immunol Res*, *3*(6), 610-619. [https://doi.org/10.1158/2326-](https://doi.org/10.1158/2326-6066.CIR-14-0138)  
377 [6066.CIR-14-0138](https://doi.org/10.1158/2326-6066.CIR-14-0138)  
378
- 379 Pilonis, K. A., Hensler, M., Daviaud, C., Kraynak, J., Fucikova, J., Galluzzi, L., Demaria, S., & Formenti,



- 380 S. C. (2020, Oct 20). Converging focal radiation and immunotherapy in a preclinical model  
381 of triple negative breast cancer: contribution of VISTA blockade. *Oncoimmunology*, *9*(1),  
382 1830524. <https://doi.org/10.1080/2162402X.2020.1830524>  
383
- 384 Piras, A., Sanfratello, A., Boldrini, L., D'Aviero, A., Pernice, G., Sortino, G., Valerio, M. R., Gennari, R.,  
385 D'Angelo, I., Marazzi, F., Angileri, T., & Daidone, A. (2023). Stereotactic Radiotherapy in  
386 Early-Stage Breast Cancer in Neoadjuvant and Exclusive Settings: A Systematic Review.  
387 *Oncol Res Treat*, *46*(3), 116-123. <https://doi.org/10.1159/000528640>  
388
- 389 Poggio, F., Bruzzone, M., Ceppi, M., Ponde, N. F., La Valle, G., Del Mastro, L., de Azambuja, E., &  
390 Lambertini, M. (2018, Jul 1). Platinum-based neoadjuvant chemotherapy in triple-  
391 negative breast cancer: a systematic review and meta-analysis. *Ann Oncol*, *29*(7), 1497-  
392 1508. <https://doi.org/10.1093/annonc/mdy127>  
393
- 394 Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kummel, S., Bergh, J., Denkert, C., Park, Y. H., Hui,  
395 R., Harbeck, N., Takahashi, M., Foukakis, T., Fasching, P. A., Cardoso, F., Untch, M., Jia, L.,  
396 Karantza, V., Zhao, J., Aktan, G., Dent, R., O'Shaughnessy, J., & Investigators, K.-. (2020,  
397 Feb 27). Pembrolizumab for Early Triple-Negative Breast Cancer. *N Engl J Med*, *382*(9),  
398 810-821. <https://doi.org/10.1056/NEJMoa1910549>  
399
- 400 Takanen, S., Pinnaro, P., Farina, I., Sperati, F., Botti, C., Vici, P., Soriani, A., Marucci, L., & Sanguineti,  
401 G. (2022). Stereotactic partial breast irradiation in primary breast cancer: A comprehensive  
402 review of the current status and future directions. *Front Oncol*, *12*, 953810.  
403 <https://doi.org/10.3389/fonc.2022.953810>  
404
- 405 Viani, G. A., Gouveia, A. G., Louie, A. V., Korzeniowski, M., Pavoni, J. F., Hamamura, A. C., & Moraes,  
406 F. Y. (2021, Nov). Stereotactic body radiotherapy to treat breast cancer oligometastases:  
407 A systematic review with meta-analysis. *Radiother Oncol*, *164*, 245-250.  
408 <https://doi.org/10.1016/j.radonc.2021.09.031>  
409
- 410 Voorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., van de Vijver, K. K., de Maaker, M., Nederlof,  
411 I., Kluin, R. J. C., Warren, S., Ong, S., Wiersma, T. G., Russell, N. S., Lalezari, F., Schouten, P.  
412 C., Bakker, N. A. M., Ketelaars, S. L. C., Peters, D., Lange, C. A. H., van Werkhoven, E., van  
413 Tinteren, H., Mandjes, I. A. M., Kemper, I., Onderwater, S., Chalabi, M., Wilgenhof, S.,  
414 Haanen, J., Salgado, R., de Visser, K. E., Sonke, G. S., Wessels, L. F. A., Linn, S. C.,  
415 Schumacher, T. N., Blank, C. U., & Kok, M. (2019, Jun). Immune induction strategies in  
416 metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the  
417 TONIC trial. *Nat Med*, *25*(6), 920-928. <https://doi.org/10.1038/s41591-019-0432-4>  
418
- 419 Wang, J., Zhou, C., Yao, W., Wang, Q., Min, X., Chen, G., Xu, X., Li, X., Xu, F., Fang, Y., Yang, R., Yu,  
420 G., Gong, Y., Zhao, J., Fan, Y., Liu, Q., Cao, L., Yao, Y., Liu, Y., Li, X., Wu, J., He, Z., Lu, K.,  
421 Jiang, L., Hu, C., Zhao, W., Zhang, B., Shi, W., Zhang, X., Cheng, Y., & Group, C.-S. (2022,

422 Jun). Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for  
423 extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised,  
424 double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*, 23(6), 739-747.  
425 [https://doi.org/10.1016/S1470-2045\(22\)00224-8](https://doi.org/10.1016/S1470-2045(22)00224-8)

426

427 Yan, W., Zhong, W. Z., Liu, Y. H., Chen, Q., Xing, W., Zhang, Q., Liu, L., Ge, D., Chen, K., Yang, F., Lin,  
428 X., Song, L., Shi, W., & Wu, Y. L. (2023, Feb). Adebrelimab (SHR-1316) in Combination With  
429 Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III  
430 NSCLCs: An Open-Label, Multicenter, Phase 1b Trial. *J Thorac Oncol*, 18(2), 194-203.  
431 <https://doi.org/10.1016/j.jtho.2022.09.222>

432

433

434

435

**Table 1. Baseline characteristics**

| <b>Characteristic</b>      | <b>Patients (n=13)</b> |
|----------------------------|------------------------|
| <b>Age (median, range)</b> | 51 (31-68)             |
| <b>Age Group, years</b>    |                        |
| ≤ 50                       | 6 (46.2%)              |
| > 50                       | 7 (53.8%)              |
| <b>Menopausal status</b>   |                        |
| Premenopausal              | 6 (46.2%)              |
| Postmenopausal             | 7 (53.8%)              |
| <b>Tumor size</b>          |                        |
| T2                         | 10 (76.9%)             |
| T3                         | 3 (23.1%)              |
| <b>Lymph node status</b>   |                        |
| N0                         | 6 (46.2%)              |
| N1                         | 2 (15.4%)              |
| N2                         | 5 (38.5%)              |
| <b>Clinical stage</b>      |                        |
| IIA                        | 6 (46.2%)              |
| IIB                        | 1 (7.7%)               |
| IIIA                       | 6 (46.2%)              |
| <b>Tumor grade</b>         |                        |
| II                         | 6 (46.2%)              |
| III                        | 5 (38.5%)              |
| Unknown                    | 2 (15.4%)              |
| <b>HER2 expression</b>     |                        |
| Negative                   | 8 (61.5%)              |
| 1+                         | 3 (23.1%)              |
| 2+, FISH-                  | 2 (15.4%)              |

436

437

**Table 2.** Pathological and clinical response

| Variable                                    | Patients (n=10) |
|---|-----------------|
| <b>Total pathological complete response</b> | 9 (90%)         |
| <b>Residual cancer burden score</b>         |                 |
| 0   | 9 (90%)         |
| I   | 1 (10%)         |
| II  | 0               |
| III   | 0               |
| <b>Radiological response</b>                |                 |
| Complete response                           | 3 (30%)         |
| Partial response                            | 7 (70%)         |
| Stable disease                              | 0               |
| Objective response rate                     | 10 (100%)       |

438

439

440

**Table 3.** Treatment-related adverse events

|   | Patients (n=13) |           |          |
|---|-----------------|-----------|----------|
|   | Grade 1 or 2    | Grade 3   | Grade 4  |
| <b>Total</b>                              | 5 (38.5%)       | 6 (46.2%) | 1 (7.7%) |
| Anemia                                    | 8 (61.5%)       | 1 (7.7%)  | 0        |
| Alopecia                                  | 9 (69.2%)       | 0         | 0        |
| Neutropenia                               | 4 (30.8%)       | 3 (23.1%) | 1 (7.7%) |
| Hyponatremia                              | 8 (61.5%)       | 0         | 0        |
| Nausea                                    | 8 (61.5%)       | 0         | 0        |
| Leukopenia                                | 6 (46.2%)       | 1 (7.7%)  | 0        |
| Lymphopenia                               | 7 (53.8%)       | 0         | 0        |
| Thrombocytopenia                          | 5 (38.5%)       | 1 (7.7%)  | 0        |
| Elevated alanine aminotransferase level   | 5 (38.5%)       | 0         | 0        |
| Elevated aspartate aminotransferase level | 5 (38.5%)       | 0         | 0        |
| Thyroid stimulating hormone decreased     | 5 (38.5%)       | 0         | 0        |
| Hyperuricemia                             | 5 (38.5%)       | 0         | 0        |
| Vomiting                                  | 5 (38.5%)       | 0         | 0        |
| Fatigue                                   | 4 (30.8%)       | 0         | 0        |
| γ-glutamyl transferase increased          | 3 (23.1%)       | 0         | 0        |
| Creatinine increased                      | 3 (23.1%)       | 0         | 0        |
| Thyroid stimulating hormone increased     | 3 (23.1%)       | 0         | 0        |
| Creatine phosphokinase elevation          | 1 (7.7%)        | 1 (7.7%)  | 0        |
| Hyperthyroidism                           | 2 (15.4%)       | 0         | 0        |
| Free thyroid hormone decreased            | 2 (15.4%)       | 0         | 0        |
| Hyperglycemia                             | 2 (15.4%)       | 0         | 0        |
| Hypokalemia                               | 2 (15.4%)       | 0         | 0        |
| Rash                                      | 2 (15.4%)       | 0         | 0        |
| Peripheral neuropathy                     | 2 (15.4%)       | 0         | 0        |
| Diarrhea                                  | 0               | 1 (7.7%)  | 0        |
| Immune mediated myositis                  | 1 (7.7%)        | 0         | 0        |
| Ventricular extrasystole                  | 1 (7.7%)        | 0         | 0        |
| Free thyroid hormone increased            | 1 (7.7%)        | 0         | 0        |
| Hypothyroidism                            | 1 (7.7%)        | 0         | 0        |
| Troponin I elevated                       | 1 (7.7%)        | 0         | 0        |
| Proteinuria                               | 1 (7.7%)        | 0         | 0        |
| Constipation                              | 1 (7.7%)        | 0         | 0        |

441

442


443 **FIGURE LEGENDS**

444 **Figure 1** Flowchart of the trial. SBRT, stereotactic body radiotherapy.

445 **Figure 2** Swimming plot which demonstrate the pCR, RCB and radiological response profile of ten  
446 modified intention-to-treat population who received radiotherapy and undergone surgery. Each  
447 round dot or column indicates a patient. Colors indicate different clinical stage. ID, identity; pCR,  
448 pathological complete response; RCB, residual cancer burden.

449

# Figure 1



## Figure 2

